Cardiome Pharma Corp. (COM.TO)


Toronto - Toronto Delayed Price. Currency in CAD
4.080.00 (0.00%)
At close: 3:19 PM EDT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open4.05
Prev Close4.08
Bid4.06 x
Ask4.23 x
Day's Range4.01 - 4.09
52wk Range3.60 - 12.25
1y Target EstN/A
Market Cap130.05M
P/E Ratio (ttm)-3.70
Beta-0.53
Volume8,705
Avg Vol (3m)12,412
Dividend & YieldN/A (N/A)
Earnings DateN/A
  • CNW Grouplast month

    Cardiome Announces Recent Insider Purchases

    Cardiome Announces Recent Insider Purchases

  • PR Newswirelast month

    Cardiome Announces Recent Insider Purchases

    VANCOUVER, Aug. 16, 2016 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) announces that Dr. William Hunter, President and CEO, Sheila Grant, Chief Operating Officer, David McMasters, General Counsel, David Dean, VP Business Development and Investor Relations, as well as a number of members of its Board of Directors, purchased an aggregate total of 108,813 common shares of Cardiome on both the TSX and the NASDAQ on August 11, 2016, August 12, 2016 and August 15, 2016.  Details of the transactions can be found on the System for Electronic Disclosure by Insiders (SEDI). The purchases were made for investment purposes.

  • Cardiome Pharma Corp. :COM-CA: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016
    Capital Cube2 months ago

    Cardiome Pharma Corp. :COM-CA: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016

    Categories: Yahoo Finance Click here to see latest analysis Cardiome Pharma Corp. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Cardiome Pharma Corp. – Acasti Pharma Inc. Class A (APO-CA) that have also reported for this period. Highlights Summary numbers: Revenues of CAD 7.62 million, Net ... Read more (Read more...)